Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by RepliCel Life Sciences, Inc. RepliCel’s Manufacturing Inspected by Japan’s PMDA July 28, 2022 From RepliCel Life Sciences, Inc. Via AccessWire Tickers REPCF TSX-V:RP CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing July 26, 2022 From RepliCel Life Sciences, Inc. Via AccessWire Tickers REPCF TSX-V:RP Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing July 26, 2022 From RepliCel Life Sciences, Inc. Via AccessWire Tickers REPCF TSX-V:RP RepliCel Announces Material Patent Milestones January 10, 2022 From RepliCel Life Sciences, Inc. Via AccessWire Topics Intellectual Property Exposures Intellectual Property Tickers REPCF TSX-V:RP RepliCel Closed Final Tranche of Strategic Investment Commitment December 21, 2021 From RepliCel Life Sciences, Inc. Via AccessWire Tickers REPCF TSX-V:RP RepliCel Terminates License Agreement with Shiseido December 21, 2021 From RepliCel Life Sciences, Inc. Via AccessWire Tickers REPCF TSX-V:RP RepliCel Ships DermaPrecise(TM) Injector Prototypes and Consumables to Independent Laboratory for Clinical Simulation Testing November 11, 2021 From RepliCel Life Sciences, Inc. Via AccessWire Tickers REPCF TSX-V:RP RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team November 09, 2021 From RepliCel Life Sciences, Inc. Via AccessWire Tickers REPCF TSX-V:RP RepliCel Announces DermaPrecise Trademark for Dermal Injector Product Line October 28, 2021 From RepliCel Life Sciences, Inc. Via AccessWire Tickers REPCF TSX-V:RP RepliCel Announces Dermal Injector Update October 27, 2021 From RepliCel Life Sciences, Inc. Via AccessWire Tickers REPCF TSX-V:RP RepliCel Files Notice of Arbitration against Shiseido Company to Resolve its License Agreement Dispute Regarding its Androgenetic Alopecia Cell Therapy October 18, 2021 From RepliCel Life Sciences, Inc. Via AccessWire Tickers REPCF TSX-V:RP RepliCel Life Sciences Appoints One of Japan's Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor October 12, 2021 From RepliCel Life Sciences, Inc. Via AccessWire Topics Economy Exposures Economy Tickers REPCF TSX-V:RP RepliCel and University of Victoria Collaboration Leads to Bioengineering Innovations, Funding, and Patents September 16, 2021 From RepliCel Life Sciences, Inc. Via AccessWire Topics Intellectual Property Exposures COVID-19 Intellectual Property Tickers REPCF TSX-V:RP RepliCel Applies for Manufacturing Approval for Its Collagen and Tissue Regeneration Cell Therapies July 07, 2021 From RepliCel Life Sciences, Inc. Via AccessWire Tickers REPCF TSX-V:RP RepliCel Adds Independent Director June 15, 2021 From RepliCel Life Sciences, Inc. Via AccessWire Topics Artificial Intelligence Exposures Artificial Intelligence Tickers REPCF TSX-V:RP RepliCel Launches Testing of Dermal Injector Units May 25, 2021 From RepliCel Life Sciences, Inc. Via AccessWire Tickers REPCF TSX-V:RP RepliCel Launches Preparations for Second Skin Rejuvenation and Tendon Regeneration Clinical Studies May 19, 2021 From RepliCel Life Sciences, Inc. Via AccessWire Tickers REPCF TSX-V:RP RepliCel Announces Appointment of Leading Dermatologist in Japan as Clinical Advisor May 17, 2021 From RepliCel Life Sciences, Inc. Via AccessWire Tickers REPCF TSX-V:RP RepliCel Launches the Next Stage of a Research Project with the University of British Columbia to Build World-Class Hair Follicle Cell Data Map May 11, 2021 From RepliCel Life Sciences, Inc. Via AccessWire Topics Intellectual Property Exposures Intellectual Property Tickers REPCF TSX-V:RP RepliCel Announces Record Year in Patents Granted May 05, 2021 From RepliCel Life Sciences, Inc. Via AccessWire Topics Intellectual Property Exposures Intellectual Property Tickers REPCF TSX-V:RP RepliCel Announces Appointment of Leading Sports Medicine Expert as Orthopedics Clinical Advisor (Japan) May 03, 2021 From RepliCel Life Sciences, Inc. Via AccessWire Tickers REPCF TSX-V:RP RepliCel Closes Second Tranche of Strategic Investment Commitment April 29, 2021 From RepliCel Life Sciences, Inc. Via AccessWire Tickers REPCF TSX-V:RP Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.